Metabolism-guided design of short-acting calcium-sensing receptor antagonists.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  ACS Medicinal Chemistry Letters

• Publication date

  2010-05-13

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/ml100058wPMID 24900198PMCID PMC4007832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists.

  2009cited by this paper
• Potential new drug targets for osteoporosis

  2009cited by this paper
• Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.

  2009cited by this paper
• Impact of OATP transporters on pharmacokinetics

  2009cited by this paper
• The discovery of novel calcium sensing receptor negative allosteric modulators.

  2009cited by this paper
• Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study

  2009cited by this paper
• Clinical update on teriparatide

  2009cited by this paper
• Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.

  2009cited by this paper
• Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: structure-activity relationships of (thioalkyl)phenoxy benzylamines.

  2008cited by this paper
• Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.

  2008cited by this paper
• Discovery of novel 1-arylmethyl pyrrolidin-2-yl ethanol amines as calcium-sensing receptor antagonists.

  2005cited by this paper
• Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone.

  2001cited by this paper
• Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats.

  2000cited by this paper
• Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

  1999cited by this paper
• Molecular Cloning and Functional Expression of Human Parathyroid Calcium Receptor cDNAs (*)

  1995cited by this paper

• Rongalite as a Sulfone Source: Sulfonylation of para-Quinone Methides and alkyl/allyl halides.

  2022cites this paper
• Synthesis and biological activities of drugs for the treatment of osteoporosis.

  2020cites this paper
• Rongalite as a sulfone source: a novel copper-catalyzed sulfur dioxide anion incorporation process.

  2020cites this paper
• Discovery and Development of Calcimimetic and Calcilytic Compounds.

  2018cites this paper
• Discovery of novel dihydrobenzofuran cyclopropane carboxylic acid based calcium sensing receptor antagonists for the treatment of osteoporosis.

  2016cites this paper
• Synthesis of sulfones from organozinc reagents, DABSO, and alkyl halides.

  2014cites this paper
• The Influence of Bioisosteres in Drug Design: Tactical Applications to Address Developability Problems

  2014cites this paper
• Metabolism-guided drug design

  2013cites this paper
• Metabolic Stability and Analogue‐Based Drug Discovery

  2012cites this paper
• Discovery of a potent and short-acting oral calcilytic with a pulsatile secretion of parathyroid hormone.

  2011cites this paper
• Calcilytics: antagonists of the calcium-sensing receptor for the treatment of osteoporosis.

  2011cites this paper
• Synopsis of some recent tactical application of bioisosteres in drug design.

  2011cites this paper